Diosmin
ApprovedSmall molecule
Diosmin is one of 168 small molecule programs targeting Menorrhagia. It is currently in Approved.
6
Indications
9
Total Trials
1
Active Trials
167
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonPhase 3
Diosmin
TTanta University
Approved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
SHR0302
RReistone Biopharma Company Limited
Phase 3
PTM SEMA
GileadPhase 3
TA-650
Tanabe Pharma CorporationPhase 3
Simponi
Johnson & JohnsonPreclinical
CT-P13 SC (infliximab)
CCelltrion
Phase 3
Remicade
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian Hyperstimulation Syndrome1 trial
Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
Completed·—·Phase 2/3·NCT02134249·200 enrolled
Menorrhagia1 trial
Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD
Unknown status·—·Phase 1/2·NCT02616731·100 enrolled
4 more indications
Efficacy and Safety1 trial
Non-Alcoholic Steatohepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diosmin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTanta University